Cytek Biosciences, Inc.
Financials
Valuation Metrics
Cytek Biosciences, Inc.'s Market Cap is $557M. At end of 2025 it was $647M. Ranked #2758 of 3,112 in US market (top 89%), #1190 of 1,445 on NASDAQ (top 82%), #167 of 206 in Health Care Equipment & Services (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $557M | US#2,758/3,112 Sec#167/206 |
| Revenue | $204M | US#2,677/3,112 Sec#176/206 |
| Net Income | $-74M | US—/3,112 Sec—/206 |
| Total Assets | $449M | US#2,786/3,112 Sec#164/206 |
| Net Assets | $328M | US#2,508/3,112 Sec#146/206 |
| Employees | 702 | US#1,316/3,112 Sec#108/206 |
| Value | ||
| P/B | 1.70x | US#989/3,112 Sec#52/206 |
| P/S | 2.73x | US#1,626/3,112 Sec#114/206 |
| FCF Yield | -2.28% | US—/3,112 Sec—/206 |
| Profitability | ||
| ROE | -22.59% | US#2,550/3,112 Sec#154/206 |
| ROA | -16.48% | US#2,741/3,112 Sec#171/206 |
| Op. Margin | -21.49% | US#2,703/3,112 Sec#171/206 |
| Revenue Growth | 6.46% | US#1,601/3,112 Sec#117/206 |
| Financial Health | ||
| Debt Ratio | 37.07% | US#424/3,112 Sec#49/206 |
| Total Debt | $36M | US#2,607/3,112 Sec#160/206 |
| FCF | $-13M | US#2,342/3,112 Sec#161/206 |
| Cash | $66M | US#2,454/3,112 Sec#158/206 |
| Current Ratio | 4.69x | US#514/3,112 Sec#47/206 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,112 Sec—/206 |
| Payout Ratio | 0.00% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 18.41% | US#1,688/3,112 Sec#119/206 |
| 1M Return | -6.10% | US#2,343/3,112 Sec#155/206 |
| From 52W High | -30.26% | US#2,189/3,112 Sec#148/206 |
| 1Y MDD | -42.86% | US#2,093/3,112 Sec#118/206 |
| Trading | ||
| Volume | 883,162 shares | US#1,583/3,112 Sec#113/206 |
| Trading Value | $4M | US#2,754/3,112 Sec#182/206 |
| Per Share | ||
| EPS | $-0.52 | US—/3,112 Sec—/206 |
| BPS | $2.66 | US#2,453/3,112 Sec#167/206 |
Company Info
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.